If you have taken Elmiron for months or years, you may wonder whether your eyes need closer monitoring. Medical research has identified certain patient groups that appear more susceptible to pigmentary maculopathy. Building on decades of pharmacovigilance science, this page explains the known risk factors and who should discuss retinal screening with their doctor.
Pigmentary maculopathy associated with Elmiron is characterized by pigmentary changes in the retina, as noted in the drug's prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). Visual symptoms reported in affected patients include difficulty reading, slow adjustment to low or reduced light environments, and blurred vision (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). The visual consequences of these pigmentary changes are not fully characterized, but they may be irreversible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). Diagnosis typically involves a comprehensive retinal examination, including color fundoscopic photography, ocular coherence tomography (OCT), and auto-fluorescence imaging (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). The prescribing information recommends obtaining a detailed ophthalmologic history before starting treatment, and for patients with pre-existing ophthalmologic conditions, a baseline retinal examination is advised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). For all patients, a baseline retinal examination within six months of initiating treatment and periodically thereafter is suggested (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593).
Elmiron is a semi-synthetic polysaccharide that is poorly understood in terms of its mechanism of action for interstitial cystitis. The drug's adverse event profile, as captured in the FDA Adverse Event Reporting System (FAERS), shows a high frequency of ocular events. The most frequently reported adverse events associated with Elmiron include maculopathy (1,382 reports), retinal pigmentation (607 reports), and pigmentary maculopathy (442 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:ELMIRON). Other notable ocular events include dry age-related macular degeneration (560 reports), macular degeneration (212 reports), and visual impairment (150 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:ELMIRON). Non-ocular events such as off-label use (1,361 reports), drug ineffective (327 reports), and pain (292 reports) are also common (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:ELMIRON). In clinical trials involving 2,627 patients, serious adverse events occurred in 1.3% of patients, with deaths attributed to other concurrent illnesses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593).
The exact mechanism by which Elmiron causes pigmentary maculopathy remains unclear. The prescribing information states that 'the etiology is unclear' but notes that cumulative dose appears to be a risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). A 21-year real-world analysis of FAERS data found that safety signals for pentosan polysulfate sodium show a distinct long-latency risk profile, with the strongest signals concentrated in the 'Eye Disorders' system organ class (https://pubmed.ncbi.nlm.nih.gov/41657558/). The analysis reported a median onset time of 1,715 days (approximately 4.7 years) for maculopathy, with a decreasing hazard rate over time (https://pubmed.ncbi.nlm.nih.gov/41657558/). This suggests that the risk is highest after prolonged exposure, consistent with the clinical observation that most cases occur after three years of use or longer (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). The majority of reported cases (68.1%) were classified as serious adverse events (https://pubmed.ncbi.nlm.nih.gov/41657558/). Gender-specific analysis revealed that maculopathy signals were prominently observed among females, while males exhibited distinct associations with gastrointestinal and urinary adverse events (https://pubmed.ncbi.nlm.nih.gov/41657558/).
The adequacy of warnings regarding Elmiron and pigmentary maculopathy is addressed in the prescribing information. The label includes a Warnings section that explicitly describes retinal pigmentary changes and their association with long-term use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). It advises caution in patients with pre-existing retinal pigment changes and recommends re-evaluating the risks and benefits of continuing treatment if pigmentary changes develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). However, the label does not specify a mandatory monitoring schedule for all patients, only suggesting a baseline examination within six months and periodic follow-up (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). For patients with a family history of hereditary pattern dystrophy, genetic testing is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). Causation-related considerations for affected patients are complex. The FAERS data show a strong signal for pigmentary maculopathy, with an exceptionally high reporting odds ratio (ROR) (https://pubmed.ncbi.nlm.nih.gov/41657558/). This pharmacovigilance evidence supports a causal association, though the mechanism is not fully understood. Patients who develop pigmentary maculopathy after long-term Elmiron use may face challenges in establishing causation, particularly if they have other risk factors for retinal disease. The label advises that examination findings may be confounded in patients with retinal pigment changes from other causes (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). The timeline between exposure and documented harm is a critical risk factor. The median onset time of 1,715 days (approximately 4.7 years) from the FAERS analysis indicates that harm typically occurs after several years of use (https://pubmed.ncbi.nlm.nih.gov/41657558/). The label notes that most cases occurred after three years or longer, but cases have been seen with a shorter duration (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). This long latency period means that patients may be exposed to the drug for years before symptoms develop, and the pigmentary changes may be irreversible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). The decreasing hazard rate over time, as indicated by the Weibull model (β = 0.62), suggests that the risk is highest in the early years of long-term use and then declines (https://pubmed.ncbi.nlm.nih.gov/41657558/).
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Elmiron (pentosan polysulfate sodium) is a medication approved for the treatment of interstitial cystitis, a chronic bladder condition. It is a semi-synthetic polysaccharide with a poorly understood mechanism of action for this indication.
Pigmentary maculopathy is a retinal condition characterized by pigmentary changes in the retina. A growing body of evidence, including data from the FDA Adverse Event Reporting System (FAERS) and pharmacovigilance analyses, has linked long-term use of Elmiron to this condition. The prescribing information includes warnings about retinal pigmentary changes associated with long-term use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593).
Visual symptoms reported in affected patients include difficulty reading, slow adjustment to low or reduced light environments, and blurred vision (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). The visual consequences may be irreversible.
Diagnosis typically involves a comprehensive retinal examination, including color fundoscopic photography, ocular coherence tomography (OCT), and auto-fluorescence imaging (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). A baseline retinal examination within six months of initiating treatment and periodically thereafter is suggested.
A 21-year real-world analysis of FAERS data reported a median onset time of 1,715 days (approximately 4.7 years) for maculopathy (https://pubmed.ncbi.nlm.nih.gov/41657558/). The prescribing information notes that most cases occurred after three years or longer, but cases have been seen with a shorter duration (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.